Johnson & Johnson Optimistic for 2025 – Growth Supported by Acquisitions and [Cancer Drugs]
Reading Time: 3 minutes
According to Johnson & Johnson CEO Joaquin Duato, 2024 was a year of transformation, characterized by strong growth, an accelerated pipeline, and industry-leading investments in innovation. The pace of growth and innovative strength were supported by the differentiated portfolio, robust pipeline, and solid financial foundation, Duato said. Cancer Drugs Drive Revenue Growth – Darzalex Becomes Top Product in 2024 The reported total revenue for 2024 increased by 4.3% to $88.8 billion, reflecting an operational growth of 5.9% and an adjusted...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
